Triad Isotopes, Inc. (Jubilant DraxImage Radiopharmacies, Inc.), Kansas City, MO

Is Triad Isotopes, Inc. (Jubilant DraxImage Radiopharmacies, Inc.) registered with the FDA as a 503B outsourcing facility?

No matching record found in FDA’s registered outsourcing facility list (updated Nov 6, 2026) on Nov 15, 2026, searching by name and location. FDA’s compounding inspections and actions page labels it a 503A facility.

Does Triad Isotopes, Inc. (Jubilant DraxImage Radiopharmacies, Inc.) hold a Missouri pharmacy license?

State board of pharmacy records for Missouri are not checked: the Division of Professional Registration’s license downloads sit on a script-driven portal, and its robots.txt file disallows the board’s pharmacy pages.

Has Triad Isotopes, Inc. (Jubilant DraxImage Radiopharmacies, Inc.) had a state board action or FDA letter?

FDA letters: record found. FDA’s compounding inspections and actions page, current as of Oct 22, 2026, lists 1 warning letter close-out (Jun 4, 2020) and 1 FMD-145 letter (Feb 4, 2025) for Triad Isotopes, Inc. (Jubilant DraxImage Radiopharmacies, Inc.). State board of pharmacy records for Missouri are not checked: the Division of Professional Registration’s license downloads sit on a script-driven portal, and its robots.txt file disallows the board’s pharmacy pages.

FDA registers 503B outsourcing facilities; state boards of pharmacy license pharmacies, including 503A compounding pharmacies, and keep their own disciplinary records. Neither FDA list says which drugs a pharmacy makes.

Names in FDA records
Jubilant DraxImage Radiopharmacies, Inc.; Triad Isotopes, Inc.
Location
Kansas City, MO
Type as FDA labels it
503A
FDA 503B list
No matching record found
Form 483s on FDA’s actions page
0
Warning letters on FDA’s actions page
0
Latest action on that page
Feb 4, 2025
FDA Data Dashboard inspections
2 inspections: 1 OAI, 1 VAI; 3 published Form 483s
Form 483 text on this page
2 Form 483s, 7 observations
State board records
Not checked

FDA inspections and letters

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this pharmacy as Jubilant DraxImage Radiopharmacies, Inc., (dba Triad Isotopes, Inc.), a 503A facility, with 2 dated actions.

Document
Feb 4, 2025FMD-145 letterFMD-145 Letter Issued 02/04/2025Not linked by FDA
Jun 4, 2020Warning letter close-outWarning Letter Close Out Issued 06/04/2020Not linked by FDA

An untitled or FMD-145 letter states FDA’s view when it was issued.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Jubilant Draximage Radiopharmacies Inc, Kansas City, MO (FEI number 3008364285), matched to this page by exact name, city and state. It lists 2 inspections: 1 OAI, 1 VAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Jul 3, 2017Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30083642851016625
Jan 9, 2015Official Action Indicated (OAI)Drug Quality Assurance (Drugs)3008364285909274

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 7 numbered observations in all, across 2 inspections ending Jan 9, 2015 to Jul 23, 2015. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection dated Jul 23, 2015 by FDA (dates on the form not read): 3 observations

Firm on the cover
Triad Isotopes Inc., 712 Westport Rd, Kansas City, MO 64111-3130
FEI number
3008364285
Establishment type on the cover
Producer of Sterile Drugs This document list observations made by the FDA representative(s) during the inspection of your facility. They are inspectional observatio ns, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an observation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with th e FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any qu estions, please contact FDA at the phone number and address above.
FDA district office on the cover
STRICT AD DRE SS AND PH ONE NUMBER 8050 Marshall Drive, Suite 205 Lenexa, KS 66214
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Clothing of personnel engaged in the manufacturing, processing, packing, and holding of drug products is not appropriate for t he duties they perform.

Specifically, your firm i s aseptically manipulating sterile ingredients and sterile components during the processing of sterile i njectable radiophannaceuticals in an ISO 5 laminar flow hood. Yo ur firm la cks adequate data to support that the following co nditions a re not compromising the sterility of your injectable drug produces.

Your operators put on noo-sterile gloves and non-sterile forearm covers, in an unclassified area that is not supplied by HEPA alt ered air, tbey spray the ir gloves with REDACTION (b)(4) and then begin to aseptically process sterile drug products and sterile components in the ISO 5 laminar flow hood.

Observation 2

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to asep tic processing of drug products.

Specifically :

1. Your fum Jacks adequate environmental monitoring data to support that your aseptic manipulation of sterile drugs and sterile components in the ISO-5 boods does not comprounise the sterility of injectable drug products. You are performing these operations REDACTION (b)(4) and you are currently monitoring

A. The original overhead covers inside your hoods were removed, apparently to allow for the installation of an electric outlet just below tbe HEPA filters, centered on the back inside wall of the hood. Your RE DACTI ON (b)(4) are plugged into that outlet. This modification created insanitary conditions above the critical ISO 5 wo rk areas. In addition to the su spended power cords, in one of your hood the two overhead florescent light bulbs are completely exposed a nd in the other hood they were partially covered by two parts of a broken, waffle-style white plastic grate.

B. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Laboratory controls do n ot include the establishment of scientifically sound and appropriate test procedures designed to ass ure that drug products conform tO appropriate standards of identity, strength, quality and purity.

Specifically, you use annual media fills to simulate the processing of sterile injectable drug products in an ISO 5 Laminar f low hood and to evaluate the aseptic technique used by the operators. You r personnel are following an improperly worded pro cedure and their filled media challenge samples are being incubated for REDACTION (b)(4) at approxim at ely RE DACTION (b)(4). These temperatures are below the optimum temperature range (25 C and 35 C) for promotin g microbial growth. This can result in false negatives for no detected microbial growth and incorrect conclusions about tbe ability of your operators t o aseptically process sterile drug products.

AMENDMENT 1

OATE lSSU~D El.IPI.OYEE(S) SIGNATVRE

B. Your vast array of on-line corporate procedures bave not been differentiated to site specific procedures, so that all of your personnel can clearly identify and understand what procedures are applicable to their responsibilities. ...

Read the full 483 (PDF on fda.gov)

Inspection Jan 5, 2015 to Jan 9, 2015: 4 observations

Firm on the cover
, COD E, C OUNTRY K ansas Ci ty, MO 64111-3130 ----------------------------~
FEI number
3008364285
Establishment type on the cover
Pro ducer of St eri le Drugs This document list observations made by the FDA representative(s) during the inspection of your facility. They are inspectional obs ervations, and do not represent a final Agency determination regarding your compliance. If you have an objection regarding an obs ervation, or have implemented, or plan to implement, corrective action in response to an observation, you may discuss the objection or action with the FDA representative(s) during the inspection or submit this information to FDA at the address above. If you have any q uestions, p lease contact FDA at the phone number and address above. or
FDA district office on the cover
Industry In formation: www.fda.gov/oc/industry D IS T RICT ADDRESS AND PHONE NUMBER 8050 Marshall Drive, Suite 205 Lenexa, KS 66214
Matched to this page by
FEI number on the cover; linked from Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

This 483 is a scanned image. The text below is the PDF’s own text layer, which can misread characters; the PDF is the record.

Observation 1

Clothing of personnel engaged in the manufacturing, processing, packing, and holding of drug productS is not appropriate for the duties they perform.

Specifically, your firm is aseptically manipulating sterile ingredients and sterile components during rbe compoutlding of sterile injectable radiopharmaceuticals in an ISO 5 laminar flow hood. Your firm lacks adequate data to support that the following conditions are not compromising !he sterility of your injectable drug products.

Your operators put on non-sterile gloves aod non-sterile forearm covers, in an unclassified area that is not supplied by HEPA filtered air, they spray their gloves with REDACTION (b)(4) and then begin to aseptically process sterile drug products a nd sterile components in the ISO 5 laminar flow hood.

Observation 2

Separate or defined areas to prevent contamination or mix-ups are deficient regarding operations related to aseptic processing of d rug products.

Specifically:

1. Your firm lacks adequate environmeotal monitoring data to support that your aseptic manipulation of sterile drugs and sterile components in the ISO-5 hoods does not compromise the s1erility of injectable drug products. You are performing these operations REDAC TION (b)(4) and you are currently monitoring:

A. Viable organisms in your ISO-5 hoods, REDACTIO N (b)(4). Since you missed your testing schedule in 9/2014 , your most recent assessment was on 3/15/2014.

A. The original overhead covers inside your hoods were removed, apparently to allow for the installation of an electric outlet just below the HEPA filters, centered on tbe back inside wall of the hood. Your REDACTION (b)(4) are p lugged into that outlet. This modification created insanitary conditions above tbe critical ISO 5 work areas. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Laboratory controls do not include the establishment of scientifically sound and appropriate test procedures designed to assure that drug products conform to appropriate standards of identity, strength, qualily and purity.

Specifically, you use annual media fills to simulate the processing of sterile injectable drug products in an ISO 5 Laminar flow hood and to evaluate the aseptic technique used by the operatOrs. Y our personnel are following an improperly worded procedure and their filled media challenge samples ar e be ing incubated fo r REDA CTION (b)(4) at approximate]y REDACTION (b)(4) These temperatures are below the optimum temperature r ange (25 C and 35 C ) for promoting microbial growth. This can result in false negatives for no detected microbial growth and incorrect conclusions about tbe ability of your pharmacists and technicians to aseptically process sterile drug products.Specifically, you use annual media fills to simulate the processing of steril e i njectable drug products in an ISO 5 Laminar flow hood and to evaluate the aseptic technique used by the operatOrs. ...

Read the full 483 (PDF on fda.gov)

Observation 4

The responsibilities and procedures applicable .to the quality control unit are not in writing and fully followed

For example:

Linked 483s whose text is not shown

State board of pharmacy records

State board of pharmacy records for Missouri are not checked: the Division of Professional Registration’s license downloads sit on a script-driven portal, and its robots.txt file disallows the board’s pharmacy pages.

Same name at other locations

FDA lists these records under the same name at another location. A shared name does not establish that they are the same firm.

This page restates FDA’s lists. A Form 483, letter or board action is not a finding by this site, and a missing record is not a finding either way. A state license is matched only on the same name, city and state. Follow each link for the original document. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.